Reference
- Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in
cirrhosis: a position statement based on the EASL Special Conference
2013. J Hepatol 2014; 60:1310-1324.
- Lin LN, Zhu Y, Che FB, Gu JL, Chen JH. Invasive fungal infections
secondary to acute-on-chronic liver failure: a retrospective study.
Mycoses 2013; 56:429-433.
- Chen J, Yang Q, Huang J, Li L. Risk factors for invasive pulmonary
aspergillosis and hospital mortality in acute-on-chronic liver failure
patients: a retrospective-cohort study. Int J Med Sci 2013;
10:1625-1631.
- Gao J, Zhang Q, Wu Y, et al. Improving survival of acute-on-chronic
liver failure patients complicated with invasive pulmonary
aspergillosis. Sci Rep 2018; 8:876.
- Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive
aspergillosis in patients with liver disease. Med Mycol 2011;
49:406-413.
- Verma N, Singh S, Taneja S, et al. Invasive fungal infections amongst
patients with acute-on-chronic liver failure at high risk for fungal
infections. Liver Int 2019; 39:503-513.
- Pearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole: a new
triazole antifungal agent. Ann Pharmacother 2003; 37:420-432.
- Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450
enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos
2003; 31:540-547.
- Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for
inadequate voriconazole plasma concentrations in intensive care unit
patients and patients with hematological malignancies. Antimicrob
Agents Chemother 2013; 57:3262-3267.
- Li ZW, Peng FH, Yan M, et al. Impact of CYP2C19 Genotype and Liver
Function on Voriconazole Pharmacokinetics in Renal Transplant
Recipients. Ther Drug Monit 2017; 39:422-428.
- Yan M, Wu ZF, Tang D, et al. The
impact of proton pump inhibitors on the pharmacokinetics of
voriconazole in vitro and in vivo. Biomed Pharmacother 2018;
108:60-64.
- Lin XB, Li ZW, Yan M, et al.
Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms
for optimizing dosing regimens in renal transplant recipients. Br J
Clin Pharmacol 2018; 84:1587-1597.
- Purkins L, Wood N, Ghahramani P, et
al. Pharmacokinetics and safety of voriconazole following intravenous-
to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;
46:2546-2553.
- Pascual A, Calandra T, Bolay S, et
al. Voriconazole therapeutic drug monitoring in patients with invasive
mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;
46:201-211.
- Wang T, Zhu H, Sun J, et al.
Efficacy and safety of voriconazole and CYP2C19 polymorphism for
optimised dosage regimens in patients with invasive fungal infections.
Int J Antimicrob Agents 2014; 44:436-442.
- Verbeeck RK. Pharmacokinetics and
dosage adjustment in patients with hepatic dysfunction. Eur J Clin
Pharmacol 2008; 64:1147-1161.
- Tang D, Song BL, Yan M, et al.
Identifying factors affecting the pharmacokinetics of voriconazole in
patients with liver dysfunction: A population pharmacokinetic
approach. Basic Clin Pharmacol Toxicol 2019; 125:34-43.
- Trang
M, Dudley MN, Bhavnani SM. Use of Monte Carlo simulation and
considerations for PK-PD targets to support antibacterial dose
selection. Curr Opin Pharmacol 2017; 36:107-113.
- Pierrat A, Gravier E, Saunders C,
et al. Predicting GFR in children and adults: a comparison of the
Cockcroft-Gault, Schwartz, and modification of diet in renal disease
formulas. Kidney Int 2003; 64:1425-1436.
- Chang Y, Burckart GJ, Lesko LJ,
Dowling TC. Evaluation of hepatic impairment dosing recommendations in
FDA-approved product labels. J Clin Pharmacol 2013; 53:962-966.
- Kamath PS, Kim WR. The model for
end-stage liver disease (MELD). Hepatology 2007; 45:797-805.
- Moriyama B, Obeng AO, Barbarino J,
et al. Clinical Pharmacogenetics Implementation Consortium (CPIC)
Guidelines for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther
2017; 102:45-51.
- Pascual A, Csajka C, Buclin T, et
al. Challenging recommended oral and intravenous voriconazole doses
for improved efficacy and safety: population pharmacokinetics-based
analysis of adult patients with invasive fungal infections. Clin
Infect Dis 2012; 55:381-390.
- Chen K, Zhang X, Ke X, et al.
Individualized Medication of Voriconazole: A Practice Guideline of the
Division of Therapeutic Drug Monitoring, Chinese Pharmacological
Society. Ther Drug Monit 2018; 40:663-674.
- Han K, Capitano B, Bies R, et al.
Bioavailability and population pharmacokinetics of voriconazole in
lung transplant recipients. Antimicrob Agents Chemother 2010;
54:4424-4431.
- Scholz I, Oberwittler H, Riedel KD,
et al. Pharmacokinetics, metabolism and bioavailability of the
triazole antifungal agent voriconazole in relation to CYP2C19
genotype. Br J Clin Pharmacol 2009; 68:906-915.
- Leveque D, Nivoix Y, Jehl F,
Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J
Antimicrob Agents 2006; 27:274-284.
- Wang T, Chen S, Sun J, et al.
Identification of factors influencing the pharmacokinetics of
voriconazole and the optimization of dosage regimens based on Monte
Carlo simulation in patients with invasive fungal infections. J
Antimicrob Chemother 2014; 69:463-470.
- Mitsani D, Nguyen MH, Shields RK,
et al. Prospective, observational study of voriconazole therapeutic
drug monitoring among lung transplant recipients receiving
prophylaxis: factors impacting levels of and associations between
serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother
2012; 56:2371-2377.
- Lamoureux F, Duflot T, Woillard JB,
et al. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing
and exposure in adult patients with invasive fungal infections. Int J
Antimicrob Agents 2016; 47:124-131.
- Li X, Yu C, Wang T, et al. Effect
of cytochrome P450 2C19 polymorphisms on the clinical outcomes of
voriconazole: a systematic review and meta-analysis. Eur J Clin
Pharmacol 2016; 72:1185-1193.
- Lee S, Kim B-H, Nam W-S, et al.
Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole
After Single and Multiple Doses in Healthy Volunteers. The Journal of
Clinical Pharmacology 2012; 52:195-203.
- Weiss J, Ten Hoevel MM, Burhenne J,
et al. CYP2C19 genotype is a major factor contributing to the highly
variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009;
49:196-204.
- Ohnishi A, Murakami S, Akizuki S,
et al. In vivo metabolic activity of CYP2C19 and CYP3A in relation to
CYP2C19 genetic polymorphism in chronic liver disease. J Clin
Pharmacol 2005; 45:1221-1229.
- Yamada T, Imai S, Koshizuka Y, et
al. Necessity for a Significant Maintenance Dosage Reduction of
Voriconazole in Patients with Severe Liver Cirrhosis (Child-Pugh Class
C). Biol Pharm Bull 2018; 41:1112-1118.
- Dolton MJ, Ray JE, Chen SC, et al. Multicenter study of voriconazole
pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents
Chemother 2012; 56:4793-4799.
- Troke PF, Hockey HP, Hope WW. Observational study of the clinical
efficacy of voriconazole and its relationship to plasma concentrations
in patients. Antimicrob Agents Chemother 2011; 55:4782-4788.